1832 Asset Management L.P. Has $95.03 Million Position in argenex SE $ARGX

1832 Asset Management L.P. lowered its stake in shares of argenex SE (NASDAQ:ARGX) by 5.9% in the second quarter, Holdings Channel reports. The firm owned 172,400 shares of the company’s stock after selling 10,900 shares during the period. 1832 Asset Management L.P.’s holdings in argenex were worth $95,030,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of ARGX. Main Management ETF Advisors LLC lifted its stake in shares of argenex by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock worth $808,000 after buying an additional 24 shares during the last quarter. IFP Advisors Inc raised its holdings in argenex by 4.2% in the 2nd quarter. IFP Advisors Inc now owns 666 shares of the company’s stock worth $367,000 after acquiring an additional 27 shares during the period. Coldstream Capital Management Inc. lifted its position in argenex by 7.6% during the 2nd quarter. Coldstream Capital Management Inc. now owns 380 shares of the company’s stock worth $209,000 after acquiring an additional 27 shares during the last quarter. Keudell Morrison Wealth Management boosted its holdings in argenex by 5.5% during the second quarter. Keudell Morrison Wealth Management now owns 534 shares of the company’s stock valued at $294,000 after acquiring an additional 28 shares during the period. Finally, Central Pacific Bank Trust Division grew its position in shares of argenex by 2.4% in the second quarter. Central Pacific Bank Trust Division now owns 1,278 shares of the company’s stock valued at $704,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Stock Up 0.7%

Shares of ARGX opened at $921.80 on Thursday. The company has a 50-day moving average price of $842.74 and a two-hundred day moving average price of $701.93. The stock has a market cap of $56.76 billion, a price-to-earnings ratio of 39.58, a P/E/G ratio of 0.92 and a beta of 0.37. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. Equities research analysts expect that argenex SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the subject of several research analyst reports. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Bank of America lifted their price target on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Jefferies Financial Group set a $818.00 price objective on argenex and gave the company a “buy” rating in a research report on Tuesday, August 26th. Wedbush boosted their target price on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research report on Friday, November 14th. Finally, JPMorgan Chase & Co. upped their target price on shares of argenex from $830.00 to $925.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $903.78.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.